merck p53 peptide patent have a patent issued - peptide-9-отзывы PEPTIDE Unraveling the Innovations: Merck's p53 Peptide Patents and Therapeutic Potential

merck-p53-peptide-vaccine-patent The p53 tumor suppressor protein is a critical guardian of the genome, playing a pivotal role in preventing cancer development. When p53 is mutated or inactivated, it can lead to uncontrolled cell growth and the progression of various malignancies. Consequently, considerable research efforts have been dedicated to understanding and therapeutically targeting the p53 pathwayMutations in the p53 Tumor Suppressor Gene - PubMed Central. A significant area of innovation lies in the development of peptides designed to modulate p53 activity, with Merck actively contributing to this field through its patent filings.APR-246 increases tumor antigenicity independent of p53 This article delves into the landscape of Merck p53 peptide patent activity, exploring the entities, LSI keywords, and variations that illuminate the quest for novel cancer therapeuticsUS8343760B2 - p53 activator peptides.

One of the central themes emerging from Merck's patent and research endeavors revolves around stabilized alpha-helix of p53 (SAH-p53) peptides. These peptides are engineered to exhibit high affinity for their key regulators, such as HDM2. Unlike their naturally occurring counterparts, these stabilized forms are designed for enhanced stability and efficacy. For instance, US Patent US9527896B2 describes such stabilized alpha-helix of p53 (SAH-p53) peptides and their various applications. The development of these specific peptides underscores a sophisticated understanding of protein-protein interactions crucial for p53 function.The present invention relates tonovel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides.

Beyond stabilization, another significant area of focus involves peptides that can reactivate p53 mutants. A substantial proportion of human cancers harbor mutated forms of p53. Reactivating these aberrant proteins or restoring their tumor-suppressive functions offers a promising therapeutic strategy.Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) | OP43 Patents like US8343760B2 highlight the development of novel polypeptides that activate p53, suggesting a broad approach to addressing p53 dysfunction.Targeting a neoantigen derived from a common TP53 ... The pursuit of such peptides is directly linked to addressing the challenge of p53-dependent drug resistance in cancers.

The involvement of Merck in this specialized field is further evidenced by entities such as MERCK PATENT and Merck Patent. Their commitment extends to various patent applications and issued patents, including those related to peptide therapeutics2023年8月9日—Astex Pharmaceuticals andMerck(MSD) have expanded their collaboration to identify small molecule candidates for cancer treatment.. For example, a patent issued (WO2014055039A1) on peptides developed through a collaborative project involving researchers associated with Merck demonstrates their engagement in advancing peptide-based interventions.p53 R175H - Drugs, Indications, Patents Furthermore, Merck has also been associated with patent applications like EP3256484A1, underscoring their ongoing investment in novel peptide technologies.

The therapeutic potential of these p53-targeting peptides is multifacetedAnti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) | OP43. They can function as inhibitors of critical p53 regulators, thereby stabilizing and reactivating the tumor suppressorUS8343760B2 - p53 activator peptides. For instance, recent research has uncovered compounds like MK-4688, an inhibitor of the HDM2–p53 interaction, as highlighted in expert opinion publications. The development of drugs specifically designed to target p53 mutations, such as Rezatapopt (PC14586), which is designed to reactivate the p53 Y220C mutation in solid tumors, exemplifies the progress in this domain. Another significant development is the exploration of ALRN-6924, a cell-penetrating stapled alpha-helical peptide. This peptide is designed to disrupt the interaction between the p53 tumor suppressor protein and its inhibitors.The RB and p53 pathways in cancer - ScienceDirect.com ALRN-6924, the first-in-class clinical stage stapled peptide, has undergone clinical trials, showcasing the translational progress of these peptide therapeuticsTargeting a neoantigen derived from a common TP53 .... Similarly, other stapled peptide candidates, like PM2, have demonstrated the ability to stabilize p53 levels.

The strategic importance of Merck in the biopharmaceutical landscape is undeniableAnti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) | OP43. Their collaborations, such as the initiative with Astex Pharmaceuticals to discover small molecule candidates for cancer treatment, and their extensive patent portfolio, signal a strong commitment to oncology research作者：S Lundsten·2020·被引用次数：24—Lane and Christopher J. Brown are involved in a collaborative project with Merck on macrocyclic peptides andhave a patent issued(WO2014055039A1) on Peptides .... The broader context of anti-p53 research includes the development of antibodies, such as the Anti-p53 (wild type) Antibody, clone PAb1620, which is known as Cellular tumor antigen p53. While antibodies represent one class of therapeutic agents, the focus on peptide therapeutics, particularly stabilized alpha-helix of p53 (SAH-p53) peptides and those that reactivate p53 mutants, represents a distinct and promising avenue for intervention.

The complexity of the p53 pathway also lends itself to the identification of biomarkers, as seen in patent EP3159696A1, which relates to p53 biomarker profiles for predicting treatment response in hyperproliferative diseases. The targeted delivery of p53-activating stapled peptides, such as VIP116 to EGFR-expressing tumors, is another sophisticated strategy being exploredRezatapopt (also known as PC14586) is the first small-moleculep53Y220C reactivator being evaluated in clinical trials. Rezatapopt was specifically designed to .... Furthermore, researchers are investigating novel approaches like targeting neoantigens derived from common TP53 mutations, as demonstrated by work that targets a cancer-associated mutant form of the p53 proteinp53 R175H - Drugs, Indications, Patents.

In conclusion, Merck's p53 peptide patent activity, alongside broader research into p53 modulation, signifies a vital contribution to the ongoing battle against cancer. The development of stabilized alpha-helix of p53 (SAH-p53) peptides, peptides that can reactivate p53 mutants, and innovative peptide designs like ALRN-6924 underscores a deep scientific understanding and a strategic commitment to bringing life-saving therapies to patients. The intricate interplay between patents, peptide engineering, and the fundamental biology of p53 continues to drive progress in oncology, promising a brighter future for cancer treatment.作者：J Michels·2024·被引用次数：4—We demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ) can enhance the immunogenicity of tumor cells directly.